ETP-46321 - CAS 1252594-99-2
Catalog number: B0084-462342
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C20H27N9O3S
Molecular Weight:
473.556
COA:
Inquire
Targets:
PI3K
Description:
ETP-46321 is a potent and orally bioavailable PI3K α, δ inhibitor with potent biochemical and cellular activity and good pharmacokinetic properties (PK) after oral dosing. ETP-46321 PK/PD studies showed time dependent downregulation of AKT(Ser473) phosphorylation, which correlates with compound levels in tumor tissue and demonstrating to be efficacious in a GEMM mouse tumor model driven by a K-Ras(G12V) oncogenic mutation. Treatment with ETP-46321 resulted in significant tumor growth inhibition.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-462342 300 mg $499 In stock
Bulk Inquiry
Purity:
>98%
Synonyms:
5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine
MSDS:
Inquire
InChIKey:
OHKDVDMWRKFZRB-UHFFFAOYSA-N
InChI:
InChI=1S/C20H27N9O3S/c1-33(30,31)29-4-2-26(3-5-29)12-16-13-28-14-17(15-10-22-20(21)23-11-15)25-19(18(28)24-16)27-6-8-32-9-7-27/h10-11,13-14H,2-9,12H2,1H3,(H2,21,22,23)
Canonical SMILES:
CS(=O)(=O)N1CCN(CC1)CC2=CN3C=C(N=C(C3=N2)N4CCOCC4)C5=CN=C(N=C5)N
Current Developer:
Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
1.Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor.
Martínez González S1, Hernández AI, Varela C, Rodríguez-Arístegui S, Lorenzo M, Rodríguez A, Rivero V, Martín JI, Saluste CG, Ramos-Lima F, Cendón E, Cebrián D, Aguirre E, Gomez-Casero E, Albarrán M, Alfonso P, García-Serelde B, Oyarzabal J, Rabal O, Mule Bioorg Med Chem Lett. 2012 May 15;22(10):3460-6. doi: 10.1016/j.bmcl.2012.03.090. Epub 2012 Mar 29.
Phosphoinositide-3-kinase (PI3K) is an important target for cancer therapeutics due to the deregulation of this signaling pathway in a wide variety of human cancers. Herein, we describe the optimization of imidazo [1,2-a] pyrazines, which allow us to identify compound 14 (ETP-46321), with potent biochemical and cellular activity and good pharmacokinetic properties (PK) after oral dosing. ETP-46321 PK/PD studies showed time dependent downregulation of AKT(Ser473) phosphorylation, which correlates with compound levels in tumor tissue and demonstrating to be efficacious in a GEMM mouse tumor model driven by a K-Ras(G12V) oncogenic mutation. Treatment with ETP-46321 resulted in significant tumor growth inhibition.
2.Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases.
Granda TG1, Cebrián D, Martínez S, Anguita PV, López EC, Link W, Merino T, Pastor J, Serelde BG, Peregrina S, Palacios I, Albarran MI, Cebriá A, Lorenzo M, Alonso P, Fominaya J, López AR, Bischoff JR. Invest New Drugs. 2013 Feb;31(1):66-76. doi: 10.1007/s10637-012-9835-5. Epub 2012 May 24.
Inhibitors of PI3K signaling are of great therapeutic interest in oncology. The phosphoinositide-3-kinase signaling pathway is activated in a variety of solid and non-solid tumors. We have identified an imidazopyrazine derivative, ETP-46321, as a potent inhibitor of PI3Kα [Formula: see text]. The compound was 6 times less potent towards PI3Kδ and more than 200 and 60 times less potent at inhibiting PI3Kβ and PI3Kγ and did not significantly inhibit the related phosphoinositide-3-kinase-related protein kinase family kinases mTOR or DNA PK (IC(50)'s > 5 μM), or an additional 287 protein kinases that were screened. ETP-46321 inhibited PI3K signaling in treated tumor cell lines, induced cell cycle arrest and inhibited VEGF-dependent sprouting of HUVEC cells. The compound was anti-proliferative and synergized with both cytotoxic and targeted therapeutics. The compound induced a reduction in the phosphorylation of Akt in U87 MG xenografts after a single treatment.
3.ETP-46321, a dual p110α/δ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis.
Aragoneses-Fenoll L1, Montes-Casado M1, Ojeda G1, Acosta YY2, Herranz J2, Martínez S3, Blanco-Aparicio C3, Criado G4, Pastor J3, Dianzani U5, Portolés P6, Rojo JM7. Biochem Pharmacol. 2016 Apr 15;106:56-69. doi: 10.1016/j.bcp.2016.02.005. Epub 2016 Feb 13.
Class IA phosphoinositide 3-kinases (PI3Ks) are essential to function of normal and tumor cells, and to modulate immune responses. T lymphocytes express high levels of p110α and p110δ class IA PI3K. Whereas the functioning of PI3K p110δ in immune and autoimmune reactions is well established, the role of p110α is less well understood. Here, a novel dual p110α/δ inhibitor (ETP-46321) and highly specific p110α (A66) or p110δ (IC87114) inhibitors have been compared concerning T cell activation in vitro, as well as the effect on responses to protein antigen and collagen-induced arthritis in vivo. In vitro activation of naive CD4(+) T lymphocytes by anti-CD3 and anti-CD28 was inhibited more effectively by the p110δ inhibitor than by the p110α inhibitor as measured by cytokine secretion (IL-2, IL-10, and IFN-γ), T-bet expression and NFAT activation. In activated CD4(+) T cells re-stimulated through CD3 and ICOS, IC87114 inhibited Akt and Erk activation, and the secretion of IL-2, IL-4, IL-17A, and IFN-γ better than A66.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PI3K Products


CAS 1173900-33-8 AZD6482

AZD6482
(CAS: 1173900-33-8)

AZD6482 is a PI3Kβ inhibitor with IC50 of 10 nM, 8-, 87- and 109-fold more selective to PI3Kβ than PI3Kδ, PI3Kα and PI3Kγ. Phase 1.

CAS 1007207-67-1 CH5132799

CH5132799
(CAS: 1007207-67-1)

CH5132799 is a novel class I PI3K inhibitor, which exhibited a strong inhibitory activity especially against PI3K; (IC(50)=0.014 uM). In human tumor cell lines ...

CAS 955977-50-1 PI-3065

PI-3065
(CAS: 955977-50-1)

PI-3065 is a novel potent and selective PI3K p110δ inhibitor with IC50 of 15 nM; exhibits > 100 fold selectivity against p110α, p110β, p110γ, DNA-PK and mTOR.

CAS 475110-96-4 ZSTK474

ZSTK474
(CAS: 475110-96-4)

ZSTK474 is a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, which strongly inhibits cancer cell proliferation. Phosphoinositide 3-kinase (PI3K) is a pote...

PQR530
(CAS: 1927857-61-1)

PQR530 is a potent dual pan PI3K/mTOR inhibitor undergoing phase II clinical trials in 2016. Aberrant activation of the PI3K/mTOR signaling pathway promotes the...

CAS 1218777-13-9 CAY10505

CAY10505
(CAS: 1218777-13-9)

CAY10505 is a phosphatidylinositol 3-kinase-γ inhibitor, was found to significantly improve acetylcholine-induced endothelium dependent relaxation, serum nitrat...

CAS 1198357-79-7 ETP 45658

ETP 45658
(CAS: 1198357-79-7)

ETP 45658 is a PI 3-kinase inhibitor (IC50 = 22, 30, 129 and 710 nM for PI 3-Kα, PI 3-Kδ, PI 3-Kβ and PI 3-Kγ, respectively), and it also inhibits DNA-PK and mT...

CAS 663619-89-4 TGX-221

TGX-221
(CAS: 663619-89-4)

TGX-221 is a potent, selective, and cell membrane permeable inhibitor of the PI3K p110β catalytic subunit. Recent studies showed that TGX-221 has antiproliferat...

CAS 1383716-46-8 VPS34 inhibitor 1

VPS34 inhibitor 1
(CAS: 1383716-46-8)

VPS34 inhibitor 1 is a potent and selective inhibitor of VPS34 (IC50= 15 nM). Vps34 is a phosphoinositide 3-kinase (PI3K) class III isoform that has attracted m...

AS 252424 bispotassium salt

AS 252424 bispotassium salt is the potassium salt form of AS 252424, which is a potent and selective PI3K p110γ inhibitor.

CAS 372196-67-3 PIK-75

PIK-75
(CAS: 372196-67-3)

PIK-75 was developed as part of a PI 3-kinase drug discovery program. PIK75 attenuates insulin stimulation of Akt/PKB in a range of cell types at 100 nM. The co...

CAS 1276105-89-5 CNX-1351

CNX-1351
(CAS: 1276105-89-5)

CNX-1351 is a selective covalent Inhibitor of PI3Kα. In an end point assay, CNX-1351 potently inhibited PI3Kα and was 20−400 times less potent against β, γ, an...

CAS 1236188-16-1 740 Y-P

740 Y-P
(CAS: 1236188-16-1)

740 Y-P is a cell-permeable phosphopeptide activator of PI3K. It binds to the p85 N- and C-terminal SH2 domains of PI3K but not to GST or the N-terminal domain ...

CAS 371935-79-4 PI-103 Hydrochloride

PI-103 Hydrochloride
(CAS: 371935-79-4)

A selective class I PI3K inhibitor; it inhibits PI3K p110 isoforms, mTOC1 and also DNA-PK; a valuable tool compound

CAS 1349796-36-6 XL 765

XL 765
(CAS: 1349796-36-6)

XL 765 is a PI3K inhibitor used for the treatment of cancers. It also suppresses DNA-PK and mTOR.

CAS 1312445-63-8 NVP-BKM120 Hydrochloride

NVP-BKM120 Hydrochloride
(CAS: 1312445-63-8)

NVP-BKM120 Hcl(BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM, respectively.

MLN1117
(CAS: 1268454-23-4)

MLN1117, also known as INK1117, is a PI3Kα inhibitor which could lead to the apoptosis and growth retardation of tumor cells expressed by PI3Kα. IC50: 15 nM.

CAS 900515-16-4 AS-252424

AS-252424
(CAS: 900515-16-4)

AS-252424 is a novel, potent PI3Kγ inhibitor (IC50 of 30 nM) with a 30-fold selectivity for PI3Kγ than PI3Kα, and low inhibitory activity towards PI3Kδ/β.

AM-0687
(CAS: 1259522-94-5)

This active molecular is a selective PI3Kδ inhibitor. PI3Kδ is hyperactivated in B-cell malignancies and plays a vital role in the B-cell receptor pathway. AM-0...

CAS 957054-30-7 GDC0941

GDC0941
(CAS: 957054-30-7)

GDC-0941 is a potent pan inhibitor of class I catalytic subunits of PI3K that inhibits p110α, β, δ, and γ with IC50 values of 3, 33, 3, and 75 nM.

Chemical Structure

CAS 1252594-99-2 ETP-46321

Quick Inquiry

Verification code

Featured Items